Summary
Synopsis
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) advocated for use in painful and inflammatory rheumatic and certain nonrheumatic conditions. It may be administered orally or rectally using a convenient once or twice daily regimen. Dosage adjustments are not usually required in the elderly or those with mild renal or hepatic impairment although it is probably prudent to start treatment at a low dosage and titrate upwards in such groups of patients.
Numerous clinical trials have confirmed that the analgesic and anti-inflammatory efficacy of naproxen is equivalent to that of the many newer and established NSAIDs with which it has been compared. The drug is effective in many rheumatic diseases such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and nonarticular rheumatism, in acute traumatic injury, and in the treatment of and prophylaxis against acute pain such as migraine, tension headache, postoperative pain, postpartum pain and pain associated with a variety of gynaecological procedures. Naproxen is also effective in treating the pain and associated symptoms of primary or secondary dysmenorrhoea, and decreases excessive blood loss in patients with menorrhagia. The adverse effect profile of naproxen is well established, particularly compared with that of many newer NSAIDs, and the drug is well tolerated.
Thus, the efficacy and tolerability of naproxen have been clearly established over many years of clinical use, and it can therefore be considered as a first-line treatment for rheumatic diseases and various pain states.
Pharmacodynamic Properties
Naproxen possesses the typical pharmacodynamic properties of the nonsteroidal class of anti-inflammatory drugs. In animal studies it exhibits dose-related anti-inflammatory, analgesic and antipyretic effects: on a weight-for-weight basis it is more potent than aspirin and phenylbutazone, and equal to or less potent than indomethacin. Its anti-inflammatory effects are still apparent in adrenalectomised animals, indicating a nonsteroidal mechanism of action. The anti-inflammatory effects of naproxen, and most of its other pharmacological effects, are generally thought to be related to its inhibition of cyclo-oxygenase and consequent decrease in prostaglandin concentrations in various fluids and tissues, including the gastric mucosa, synovial fluid, urine and blood.
In common with other NSAIDs naproxen may induce gastrointestinal microbleeding and endoscopically proven gastrointestinal lesions: it generally produces less effects than aspirin and indomethacin but more than diflunisal, etodolac, nabumetone and sulindac. In clinical practice, however, while the gastrointestinal tolerability of naproxen is better than that of aspirin and indomethacin, there is no definitive evidence to suggest significant differences in tolerability (minor complaints, bleeding or ulceration) between naproxen and other NSAIDs.
Naproxen, like other NSAIDs, is a potent inhibitor of the secondary phase of platelet aggregation. However, at usual therapeutic dosages it has little effect on bleeding time in humans. In general, naproxen does not produce detrimental renal effects in patients with normal renal function although a few changes were reported in some patients with preexisting renal impairment or heart failure. Naproxen does not exert a uricosuric effect.
In normal animals naproxen does not affect collagen metabolism but can inhibit cartilage and bone erosions in animals with adjuvant-induced arthritis. There is no definitive evidence in humans with rheumatic disease that naproxen or any other NSAID can inhibit the progression of cartilage or bone destruction. As occurs with other NSAIDs, naproxen affects leucocyte function reducing chemotaxis, and lysosomal and neutral protease, and collagenase activities in animals.
Pharmacokinetic Properties
Naproxen is available in 2 forms: the free acid or the sodium salt. Naproxen and naproxen sodium are pharmacologically and therapeutically equivalent at comparable dosages (naproxen 500mg equals naproxen sodium 550mg). The only difference between the 2 forms is their rate of absorption: naproxen sodium dissolves more rapidly in gastric juice and consequently produces earlier and higher plasma concentrations. Peak plasma concentrations are achieved in about 1 hour with naproxen sodium and 2 hours with naproxen. It is possible that this may provide a faster onset of action with the sodium salt after an initial dose; this would be of relevance in the treatment of acute pain states. Apart from this difference, the post-absorption phase pharmacokinetics of the sodium salt and its parent acid are identical.
Naproxen is completely absorbed after oral and rectal administration. Concomitant administration of food may delay the absorption of orally administered naproxen but does not reduce the extent. Absorption is slower after rectal compared with oral administration, leading to a delay in and lower peak plasma concentrations. Plasma concentrations rise proportionately with dose after oral administration of single doses up to 500mg, but thereafter the increase is less than linear. This is related to increased clearance caused by saturable protein binding. Naproxen is highly protein bound (> 99.5%): the free fraction, however, increases significantly at higher plasma concentrations. The volume of distribution of naproxen is small, being about 10% of bodyweight. The drug readily reaches the synovial fluid and synovial membrane. Naproxen crosses the placental barrier, and minimal transfer occurs to breast milk (about 1% of maternal plasma samples). Approximately 95% of a radiolabelled dose of naproxen is recovered in urine and 3% or less in faeces. 70% of the drug is excreted as unchanged naproxen and the remainder is metabolised to an inactive 6-demethyl metabolite, probably by hepatic microsomal oxidation. The parent compound and metabolite are excreted free or as glucuronide or sulphate conjugates. The elimination half-life is about 12 to 15 hours.
The pharmacokinetic profile of naproxen is generally unaffected to any clinically significant extent by age or the presence of disease. However, free plasma concentrations of naproxen may be increased in elderly patients with rheumatoid arthritis and in patients with hepatic impairment, due to decreased plasma albumin levels. Renal insufficiency has little effect on the pharmacokinetics of naproxen until it is severe. When creatinine clearance is less than 10 ml/min there is a significant decrease in plasma naproxen concentration but an increase in metabolite concentrations. Naproxen is not removed by haemodialysis. Dosage reductions are not therefore required in patients with mild to moderate renal impairment and neither is dose supplementation after haemodialysis.
Therapeutic Use
Naproxen, usually 500 to 1000 mg/day on a once or twice daily basis, administered orally or rectally, has been well studied in controlled clinical trials in patients with rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. The drug shows similar analgesic and anti-inflammatory efficacy to usual therapeutic dosages of other commonly used NSAIDs (e.g. aspirin, diclofenac, ibuprofen, indomethacin, ketoprofen, piroxicam), and other less frequently used or newer NSAIDs. As would be expected in such a large number of comparisons, statistically significant differences were found for some assessment parameters but these differences were not of clinical significance and usually related to comparison of therapeutically nonequivalent dosages. With appropriate dosage titration, clinical response to NSAIDs generally appears equivalent (although individual patients may inexplicably respond to or tolerate one NSAID and not others). The therapeutic efficacy of naproxen is maintained during long term treatment up to several years and is associated with a steroid-sparing effect in patients with rheumatoid arthritis.
Several studies have shown that naproxen is effective in the treatment of acute gout and juvenile arthritis but further study is required to allow any definite conclusions concerning its efficacy and tolerability compared with other commonly used agents. Naproxen up to 1000 mg/day has been demonstrated to be an effective analgesic and anti-inflammatory agent for the treatment of acute or chronic nonarticular rheumatic conditions and soft tissue injuries. Its efficacy in these conditions is comparable to that of other commonly used agents. Naproxen is a useful analgesic in a variety of acute pain states, such as migraine, tension headache, postoperative pain, postpartum pain and pain associated with a variety of gynaecological procedures. In the treatment of acute migraine naproxen was comparable to ergotamine. In other acute pain states naproxen was at least as effective as some of the more commonly used ‘pure’ analgesics or their combinations [e.g. paracetamol (acetaminophen), codeine, dextropropoxyphene]. Naproxen has also been used successfully in the prophylaxis of migraine, reducing the severity and frequency of migraine attacks to a similar extent as pizotifen and propranolol.
Naproxen is a well studied agent in the treatment of primary and secondary dysmenorrhoea, alleviating pain and associated symptoms. It reduces symptoms at least as well as other NSAIDs with which it has been compared. In addition, naproxen reduces blood loss and anaemia consequent to menorrhagia.
Naproxen appears to be a particularly effective agent in the control of neoplastic fever and has been used to differentiate between neoplasm-related and infection-related pyrexia in cancer patients with fever of unknown origin. It may also be effective as a general antipyretic agent although further study is required to compare its efficacy relative to that of other standard treatments.
Adverse Effects
The tolerability profile of naproxen is well established, as extensive experience has been gained with the drug over many years. The drug is generally well tolerated. In common with other NSAIDs the most frequent adverse effects include mild gastrointestinal disturbances and CNS effects, followed by occasional mild skin reactions. Increased age does not appear related to any increase in unwanted effects and there is little evidence to suggest that the nature, severity or frequency of adverse effects is any different with naproxen compared with other NSAIDs. Despite some claims of improved tolerability with some newer NSAIDs, there are no definitive findings to show this. Aspirin and indomethacin may produce a higher frequency of gastrointestinal symptoms and CNS effects compared with naproxen.
As with any drug which has been used so extensively in clinical practice, a number of rare serious adverse effects have been associated with naproxen, which have also been associated with other NSAIDs. They include: gastrointestinal bleeding or ulceration, pseudoporphyria and other severe cutaneous reactions; acute renal failure including papillary necrosis, interstitial nephritis and hyperkalaemia; hepatitis; pulmonary infiltrates with eosinophilia; agranulocytosis; aplastic anaemia; haemolytic anaemia; peripheral neuropathy; aseptic meningitis; and corneal opacity. Patients exhibiting aspirin hypersensitivity may show cross-reactivity with naproxen.
Dosage and Administration
The following dosage schedule refers to naproxen administered as the free acid. If naproxen sodium is used, the dosage is increased by 10% to achieve bioequivalence (naproxen 500mg=naproxen sodium 550mg).
The usual adult maintenance dosage of naproxen in patients with chronic rheumatic disease or chronic pain is 375 to 1000 mg/day after food and on a once or twice daily basis. This may be increased to 1500 mg/day in divided doses for up to 2 weeks to treat acute exacerbations of the disease. For children with juvenile arthritis the recommended dosage is 10 mg/kg in 2 divided doses; a suspension formulation is available to aid administration. In patients with acute conditions such as tendinitis, bursitis, dysmenorrhoea and mild to moderate pain an initial loading dose of 500mg should be administered and followed by 250mg every 6 to 8 hours as required (up to a maximum of 1250 mg/day).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aabakken L, Bjørnbeth BA, Hofstad B, Olaussen B, Larsen S, et al. Comparison of the gastrointestinal side effects of naproxen formulated as plain tablets, enteric-coated tablets, or enteric-coated granules in capsules. Scandinavian Journal of Gastroenterology 24 (Suppl. 163): 65–73, 1989
Aadland E, Fausa O, Vatn M, Cohen H, Quinlan D. Protection by misoprostol against naproxen-induced gastric mucosal damage. American Journal of Medicine 83 (Suppl. 1A): 37–40, 1987
Abate MA, Layne R, Neely J, Alessandri RD. Effect of naproxen and sulindac on the blood-pressure response to atenolol. Abstract. Clinical Research 36: 738A, 1988
Abramson S, Korchak H, Ludewig R, Edelson H, Haines K, et al. Modes of action of aspirin-like drugs. Proceedings of the National Academy of Sciences 82: 7227–7231, 1985
Ackerman NR, Kappas K, Maloney P. Possible disease-modifying effects of naproxen in the adjuvant-arthritic rat. Agents and Action 15: 428–434, 1984
Aghababian RV, Volturo GA, Heifetz IN. Comparison of diflunisal and naproxen in the management of acute low back strain. Clinical Therapeutics 9 (Suppl. C): 47–51, 1986
Al-Kurdi M, Hare MJ, Lowles I, Douglas CP. The effect of a prostaglandin-synthetase inhibitor, naproxen sodium, and a placebo on the pain response to carbon dioxide laser treatment of the uterine cervix. Journal of Obstetrics and Gynecology 5: 260–262, 1985
Allen B, Edwards IR. A safety profile of controlled release naproxen tablets. New Zealand Medical Journal 102: 310–312, 1989
Alun-Jones E, Williams J. Hyponatremia and fluid retention in a neonate associated with maternal naproxen overdosage. Clinical Toxicology 24: 257–260, 1986
Amundsen T, Bleken L, Børkje B, Eidsaunet W, Eidsbø P, et al. Variation in response to naproxen and diclofenac in patients with osteoarthritis. Current Therapeutic Research 33: 793–801, 1983
Anderson LA, Gøtzsche PC. Naproxen and aspirin in acute musculoskeletal disorders: a double-blind, parallel study in patients with sports injuries. Pharmatherapeutica 3: 531–537, 1984
Andersson PG, Hinge HH, Johansen O, Andersen CV, Ladermann A, et al. Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks. Cephalalgia 9: 29–32, 1989
Andrade D, Gutiérez-Méndez G, García-Miranda R. Evolución clinica de los esguinces de tobillo tratados con diclofenac potásico y naproxén sódico. Investigación Médica Internacional 11: 130–134, 1984
Andrejak M, Davion T, Cueston JL, Capron JP. Cross hepatotoxicity between non-steroidal anti-inflammatory drugs. British Medical Journal 295: 180–181, 1987
Aoki T, Kawaji W, Kuroki Y, Sugaro T, Murota K, et al. Assessment of the clinical usefulness of nabumetone in the treatment of lower back pain, shoulder-arm-neck syndrome and adhesive capsulitis of the shoulder. Shinyaku to Rinsho 37: 2–21, 1988
Arnold K, Heimpel H. Aplastic anaemia after naproxen? Lancet 1: 321, 1980
Arramon JY, Cayla F, Clement A, Dure B, Franck JL, et al. Action antalgique et tolérance du carbasalate calcique dans les gonarthroses. Etude comparative versus naproxène versus placebo. Semaine des Hôpitaux 63: 1297–1300, 1987
Arumugham R, Bose SM. Effect of indomethacin and naproxen on the metabolism of glycosaminoglycans. Scandinavian Journal of Rheumatology 11: 225–229, 1982
Australian National Drug Information Service. Profile on naproxen. Australian Journal of Pharmacy 68: 625–639, 1987
Azeemuddin SK, Vega RA, Kim TH, Ragab AH. The effect of naproxen on fever in children with malignancies. Cancer 59: 1966–1968, 1987
Backhouse CI. Naproxen and piroxicam in the treatment of osteoarthritis. Clinical Rheumatology 5: 273, 1986
Bar M, Burke M, Isakov A, Almog C. Reversible, nonoliguric acute renal failure in a patient with rheumatoid arthritis and renal amyloidosis. New York State Journal of Medicine 86: 542–543, 1986
Barter DAC. Hair loss in a child associated with naproxen. British Medical Journal 298: 325, 1989
Barth JH, Dawber RPR. Drug induced hair loss. British Medical Journal 298: 675, 1989
Bassleer C. Effect of naproxen on cartilage matrix. Presented at the 17th ILAR Congress of Rheumatology, Sep 17–23, Rio de Janeiro, 1989
Baumgartner H, Hohmeister R, Blumenberg-Novaselac N. An observer-blind crossover study to compare the efficacies of flurbiprofen, indomethacin and naproxen given orally and rectally in the relief of night pain and morning stiffness due to rheumatoid arthritis. Journal of International Medical Research 16: 189–196, 1988
Baumgartner H, Kuttelwascher M, McCaskey D, Winters L. The comparative efficacy of naproxen sodium and pirprofen in the treatment of post-operative pain. Journal of International Medical Research 15: 179–187, 1987
Beermann B, Eriksson LO, Kallner M. A double-blind comparison of naproxen and sulindac in female patients with heart failure. Scandinavian Journal of Rheumatology 15 (Suppl. 62): 32–35, 1986
Behan PO, Connelly K. Prophylaxis of migraine: a comparison between naproxen sodium and pizotifen. Headache 26: 237–239, 1986
Bendvold E, Gottlieb C, Svanborg K, Bygdeman M, Eneroth P, et al. The effect of naproxen on the concentration of prostaglandins in human seminal fluid. Fertility and Sterility 43: 922–926, 1985
Berry H, Bloom B, Fernandes L, Morris M. Comparison of timegadine and naproxen in rheumatoid arthritis. A placebo controlled trial. Clinical Rheumatology 2: 357–361, 1983a
Berry H, Coquelin J-P, Gordon A, Seymour D. Antrafenine, naproxen and placebo in osteoarthritis: a comparative study. British Journal of Rheumatology 22: 89–94, 1983b
Berry H, Nicholls A. An open study of 1.5g naproxen daily in osteoarthritis. Current Medical Research and Opinion 9: 366–370, 1985
Berté F, Feletti F, De Bernardi di Valserra M, Nazzari M, Cenedese A, et al. Lack of influence of sulglycotide on naproxen bioavailability in healthy volunteers. International Journal of Clinical Pharmacology, Therapy and Toxicology 26: 125–128, 1988
Beveridge K. Treatment of sports injuries with naproxen sodium and dextropropoxyphene napsylate. Pharmatherapeutica 4: 393–398, 1985
Bjarnason I, Williams P, So A, Zonelli GD, Levi AJ, et al. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet 2: 1171–1174, 1984
Björkenheim J-M, Heiland J, Peltonen J. A double-blind crossover evaluation of naproxen and piroxicam in osteoarthritis of hip or knee. Journal of International Medical Research 13: 263–269, 1985
Blagbrough IS, Daykin MM, Doherty M, Pattrick M, Shaw PN. Synovial fluid and plasma levels of naproxen in osteoarthritis. Journal of Pharmacy and Pharmacology 40 (Suppl C): 153, 1988
Blaine EH, Haley A, Nelson B. Adverse renal actions of NSAIDs: comparison of sulindac sulfide (SS) and naproxen (N). Abstract no. 3415. Federation Proceedings 42: 875, 1983
Bloomfield SS, Cissell GB, Peters NM, Mitchell J, Nelson ED, et al. Anirolac vs. naproxen for postpartum pain. Clinical Pharmacology and Therapeutics 42: 89–95, 1987
Blum M, Pery J. Prevention of iron deficiency anemia in IUD users by prostaglandin synthetase inhibitors. Contraceptive Delivery Systems 5: 21–23, 1984
Bodiwala GG. Naproxen sodium and ibuprofen in the treatment of acute soft-tissue injuries. British Journal of Clinical Practice 36: 270–275, 1982
Bouchier-Hayes TAI. Naproxen sodium and piroxicam in acute musculo-skeletal disorders. British Journal of Sports Medicine 18: 80–83, 1984
Boussina I, Vischer TL. Efficacy and tolerance of naproxen versus pirprofen in the treatment of patients with osteoarthritis. Pharmatherapeutica 5: 16–20, 1987
Brater DC, Anderson S, Baird B, Campbell WB. Effects of ibuprofen, naproxen, and sulindac on prostaglandins in men. Kidney International 27: 66–73, 1985
Bravo CA. Carprofeno, nuevo antiinflammatorio no esteroide útil en la enfermedad articular degenerativa. Estudio doble ciegcon 100 pacientes. Investigatión Médica Internacional 13: 131–137, 1986
Brighton SW, de la Harpe AL. Comparison of isoxicam and naproxen in patients with rheumatoid arthritis. South African Medical Journal 68: 232–234, 1985
Brobyn RD. Nabumetone in the treatment of active adult rheumatoid arthritis. American Journal of Medicine 83 (Suppl. 4B): 50–54, 1987
Brogden RN, Heel RC, Speight TM, Avery GS. Naproxen up to date: a review of its pharmacological properties and therapeutic efficacy and use in rheumatic diseases and pain states. Drugs 18: 241–277, 1979
Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS. Naproxen: a review of its pharmacological properties and therapeutic efficacy and use. Drugs 9: 326–363, 1975
Brooks PM, Cleland LG, Haski AL, Hempton DB, Müller JN, et al. Evaluation of a single daily dose of naproxen in osteoarthritis. Rheumatology and Rehabilitation 21: 242–246, 1982
Brown BL, Johnson JH, Stiger TR. Flurbiprofen versus naproxen in the treatment of rheumatoid arthritis. American Journal of Medicine 80 (Suppl. 3A): 105–109, 1986
Brown CR, Seveluis H, Wild V. A comparison of single doses of naproxen sodium, morphine sulfate, and placebo in patients with postoperative pain. Current Therapeutic Research 35: 511–518, 1984
Bruno R, Gliadis A, Jullien I, Guego M, Pinhas H, et al. Naproxen kinetics in synovial fluid of patients with osteoarthritis. British Journal of Clinical Pharmacology 26: 41–44, 1988
Buckingham B, Eriksen E, Uitto J, Larsen M, Kershnar A. Effect of naproxen on collagen cross-linkage in type I diabetes. Abstract no. 754. Diabetes 36 (Suppl. 1): 198A, 1987
Buscaglia AJ, Cowden FE, Brill H. Pulmonary infiltrates associated with naproxen. Journal of the American Medical Association 251: 65–66, 1984
Buttram VC, Gravlee LC, Hale RW, Lifshitz S. Naproxen sodium vs a combination of aspirin, phenacetin, caffeine and codeine phosphate for pain after major gynecologic surgery. Journal of Reproductive Medicine 29: 189–192, 1984
Buttram V, Izu A, Henzl MR. Naproxen sodium in uterine pain following intrauterine contraceptive device insertion. American Journal of Obstetrics and Gynecology 134: 575–578, 1979
Caille G, du Souich P, Gervais P, Besner JG, Vezina M. Effects of concurrent sucralfate administration on pharmacokinetics of naproxen. American Journal of Medicine 83 (Suppl. 3B): 67–73, 1987a
Caille G, du Souich P, Gervais P, Besner JG. Single-dose pharmacokinetics of ketoprofen, indomethacin, and naproxen taken alone or with sucralfate. Biopharmaceutics and Drug Disposition 8: 173–183, 1987b
Calvo MV, Dominguez-Gil A. Binding of naproxen to human albumin. Interaction of palmitic acid. International Journal of Pharmaceutics 16: 215–223, 1983
Calvo MV, Dominguez-Gil A. Interaction of naproxen with cholestyramine. Biopharmaceutics and Drug Disposition 5: 33–42, 1984
Campana A, Ruspa M. Therapeutic efficacy of naproxen-lysin in dysmenorrhoea. A double-blind study v. naproxen. Clinical Trials Journal 23: 249–256, 1986
Cardoe N, Dudley Hart F. Double-blind multicentre UK hospital studies of isoxicam vs naproxen. British Journal of Clinical Pharmacology 22 (Suppl.): 167S–172S, 1986
Caruana RJ, Semble EL. Renal papillary necrosis due to naproxen. Journal of Rheumatology 11: 90–91, 1984
Castillo SS, Absaton MAH, Valencia MFG. Antipiresis aguda con una nuera asociación (naproxén sôdico y acetaminofér) en padecimientos febriles. Investigación Médica Internacional 10: 60–65, 1983
Ceccarini G, Maione AM. Variations of optical rotation of naproxen: polarimetric determination in the presence of non-chiral basic compounds. Journal of Pharmaceutical Sciences 78: 1053–1054, 1989
Ceuppens JL, Robaeys G, Verdicket W, Vertessen S, Deckmyn H, et al. Immunomodulatory effects of treatment with naproxen in patients with rheumatic disease. Arthritis and Rheumatism 29: 305–311, 1986
Chalmers JP, West MJ, Wing LMH, Bune AJC, Graham JR. Effects of indomethacin, sulindac, naproxen, aspirin, and paracetamol in treated hypertensive patients. Clinical and Experimental Hypertension Part A —Theory and Practice A 6: 1077–1093, 1984
Chang JC, Gross HM. Neoplasic fever responds to the treatment of an adequate dose of naproxen. Journal of Clinical Oncology 3: 552–558, 1985
Chang JC. How to differentiate neoplastic fever from infectious fever in patients with cancer: usefulness of the naproxen test. Heart and Lung 16: 122–127, 1987
Chang JC. Antipyretic effect of naproxen and corticosteroids on neoplastic fever. Journal of Pain and Symptom Management 3: 141–144, 1988
Chang JC. Naproxen test in the differential diagnosis of fever of undetermined origin in patients with cancer. Cancer Therapy and Control 1: 57–66, 1989a
Chang JC. Neoplastic fever: a proposal for diagnosis. Archives of Internal Medicine 149: 1728–1730, 1989b
Cherie-Ligniere G, Colamussi V, Cozzolongo AC, Loizzi P, Prizziero L, et al. A multicentre comparison of flurbiprofen and naproxen in rheumatoid arthritis: a four-week study in 118 patients. Journal of International Medical Research 11: 85–89, 1983
Chin RC, Cheng Y. Comparison of the inhibitory effect of selected nonstcroidal anti-inflammatory drugs (NSAIDs) on bone resorption induced by intcrlcukin IB. Transactions of the 35th Annual Meeting of the Orthopaedic Research Society, p. 119, Feb 6–9, Las Vegas, 1989
Chlud K, Pangerl S. Comparison of naproxen and piroxicam in the treatment of rheumatoid arthritis: a double-blind, crossover study. Pharmathcrapeutica 4: 113–121, 1985
Chopra SK, Herdman CP, Laws D, Thomas AM, Wood P. The treatment of osteo-arthritis in general practice. Clinical Trials Journal 26: 401–410, 1989
Cleland LG. Microbleeding in 28-day naproxen controlled-release (Naprosyn® SR) therapy. Clinical Trials Journal 25: 103–108, 1988
Cohen A, Basch C. Steady state pharmacokinctics of naproxen in young and elderly healthy volunteers. Seminars in Arthritis and Rheumatism 17 (Suppl. 2): 7–11, 1988
Cohen A, Ganzalcz MA, Mroszezak EJ, Yec J. Evaluation of the pharmacokinctics of naproxen from a 500mg controllcd-rclease tablet. Current Therapeutic Research 43: 1109–1117, 1988
Constantine G, Hale K, Brennan C, Eccleston D. Vaginal absorption of naproxen. Journal of Clinical Pharmacy and Therapeutics 12: 193–196, 1987
Corell T, Hasselmann G. Pharmacodynamics and toxicology of fenflunizole, a new non-steroidal anti-inflammatory imidazole derivative. Acta Pharmacologica et Toxicologica 53: 288–296, 1983
Csapo AI, Pulkkinen MO, Henz CMR. The effect of naproxensodium on the intrauterine pressure and menstrual pain of dysmenorrhoeic patients. Prostaglandins 13: 193–199, 1977
CSM Update. Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions —2. British Medical Journal 292: 1190–1191, 1986
D’Agostini G, Liberman J. Estudio clinico multicentrico en America Latina (249 parientes) con una dosisdiaria matutina de 1000mg de naproxen en osteoarthritis. Revista Brasileira de Medicina 42: 77–86, 1985
Dahl H. Naproxen (Naprosyn®). Pharmacokinctics: therapeutical relevance and tolerance profile. Cephalalgia 6 (Suppl. 4): 69–75, 1986
Davies AJ. Reduction of menstrual blood loss by naproxen in intrauterine contraceptive device users. International Journal of Gynaecology and Obstetrics 17: 353–354, 1986
Davies AJ, Anderson ABM, Turnbull AC. Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstetrics and Gynecology 57: 74–78, 1981
Day RO, Furst DE, Dromgoole SH, Kamm B, Roe R, et al. Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis. Clinical Pharmacology and Therapeutics 31: 733–740, 1982
Deal CL, Moskowitz RW. Efficacy of diflunisal versus naproxen in osteoarthritis of the knee: an open study. Clinical Therapeutics 9 (Suppl. C): 1–14, 1986
Devereaux MD, Douglas WAC. A double-blind, comparative study of diflunisal and naproxen in the treatment of rheumatoid arthritis. European Journal of Rheumatology and Inflammation 6: 274–278, 1983
Díaz-Jouanen E. Treatamiento del dolor en osteoartrosis sintomática effecto de diflunisal vs. naproxen. Investigación Médica Internacional 9 (Suppl. 2): 5–8, 1982
Diffey BL, Daymond TJ, Fairgreaves H. Phototoxic reactions to piroxicam, naproxen and tiaprofenic acid. British Journal of Rheumatology 22: 239–242, 1983
Dixey JJ, Noormohamed FH, Lant AF, Brewerton DA. The effects of naproxen and sulindac on renal function and their interaction with hydrochlorothiazide and piretanide in man. British Journal of Clinical Pharmacology 23: 55–63, 1987
Drez D, Ritter M, Rosenberg TD. Pain relief after arthroscopy: naproxen sodium compared to propoxyphene napsylate with acetaminophen. Southern Medical Journal 80: 440–443, 1987
Dueholm S, Forrest M, Hjorstø E, Lemrigh E. Pain relief following herniotomy: a double-blind randomized comparison between naproxen and placebo. Acta Anaesthesiologica Scandinavica 33: 391–394, 1989
Dunagan FM, McGill PE, Kelman AW, Whiting B. Naproxen dose and concentration: response relationship in rheumatoid arthritis. British Journal of Rheumatology 27: 48–53, 1988
Dunn NA, Mahida BH, Merrick MV, Nuki G. Quantitative sacroiliac scintis canning: a sensitive and objective method for assessing efficacy of nonsteroidal, anti-inflammatory drugs in patients with sacroiliitis. Annals of the Rheumatic Diseases 43: 157–159, 1984
Edgren RA, Morton CJ. Naproxen sodium for OB/GYN use, with special reference to pain states: a review. International Journal of Fertility 31: 135–142, 1986
Edlund A, Berglund B, van Dorne D, Kaijser L, Nowak J, et al. Coronary flow regulation in patients with ischemic heart disease: release of purines and prostacyclin and the effect of inhibitors of prostaglandin formation. Circulation 71: 1113–1120, 1985
Efron N, Holden BA, Vannas A. Prostaglandin-inhibitor naproxen does not affect contact lens-induced changes in the human corneal endothelium. American Journal of Optometry and Phsyiological Optics 61: 741–744, 1984
Eidsaunet W, Borkje B, Larsen S, Sandvik L, Spongeen KL. Response to two NSAIDs: diclofenac and naproxen in rheumatoid arthritis. Current Therapeutic Research 33: 966–975, 1983
Eliakim R, Ophir M, Rachilewitz D. Duodenal mucosal injury with nonsteroidal antiinflammatory drugs. Journal of Clinical Gastroenterology 9: 395–399, 1987
Eriksson L-O, Beerman B, Kallner M. Renal function and tubular transport effects of sulindac and naproxen in chronic heart failure. Clinical Pharmacology and Therapeutics 42: 646–654, 1987
Escalante Triay FJ. Comparative clinical study of tiaprofenic acid vs. naproxen in patients with osteoarthritis of the knee. Investigación Médica Internacional 8: 218, 1981
Esprito Santo J, Pereira da Silva J, Teixeira da Costa J, Melo Gomes J, Viana Queiroz M. Double-blind evaluation of low-dose proglumetacin versus naproxen in rheumatoid arthritis out-patients. Current Medical Research and Opinion 8: 524–530, 1983
Ezra E, Caspi I, Weiss J, Lin E, Horoszowsky H. Acute reversible renal failure following naproxen (Naxyn) administration. Scandinavian Journal of Rheumatology 15: 401–402, 1986
Farr PM, Diffey BL. Pseudoporphyria due to naproxen. Lancet 1: 1166–1167, 1985
Fedell R, Strand LJ. Naproxen overdosage. Journal of the American Medical Association 238: 938, 1977
Fenton SF, Ryan JP, Bensen WG. A double-blind, crossover, multicenter study of piroxicam and naproxen in rheumatoid arthritis. Current Therapeutic Research 44: 1058–1070, 1988
Fioravanti A, Vaccai D, Dragonetti C, Iudice A, Marcolongo R. Single-blind, randomized, parallel-group study of etodolac and naproxen in patients with osteoarthritis. Current Therapeutic Research 46: 648–653, 1989
Flint KC, Johnson NM. Pulmonary eosinophilia associated with naproxen therapy. Journal of the Royal Society of Medicine 80: 120–121, 1987
Forbes JA, Keller CK, Smith JW, Zeleznock JR, Sevelius H, et al. Analgesic effect of naproxen sodium, codeine, a naproxencodeine combination and aspirin on the postoperative pain of oral surgery. Pharmacotherapy 6: 211–218, 1986
Fossaluzza V, Montagnani G. Efficacy and tolerability of nimesulide in elderly patients with osteoarthritis: double-blind trial versus naproxen. Journal of International Medical Research 17: 295–303, 1989
Franchimont P, Bassleer C, Henrotin Y. In vitro effects of naproxen on human chondrocytes. Presented at EULAR, Nov 10–12, Paris, 1988
Frankhof W. Controlled-release naproxen compared with isoxicam in patients with osteoarthritis. Current Medical Research and Opinion 11: 28–33, 1988
Frewin DB. The effect of naproxen therapy on the blood pressure control of hypertensives treated with bevantolol. Abstract no. 112. Clinical and Experimental Pharmacology and Physiology Suppl. 11, 1987
Fulkerson JP, Folcik MA. Comparison of diflunisal and naproxen for relief of anterior knee pain. Clinical Therapeutics 9 (Suppl. C): 59–61, 1986
Furst DE, Blocka K, Cassell S, Harris EF, Hirschberg JM, et al. A controlled study of concurrent therapy with a nonacetylated salicylate and naproxen in rheumatoid arthritis. Arthritis and Rheumatism 30: 146–154, 1987a
Furst DE, Sarkissian E, Blocka K, Cassell S, Dromgoole S, et al. Serum concentrations of salicylate and naproxen during concurrent therapy in patients with rheumatoid arthritis. Arthritis and Rheumatism 30: 1157–1161, 1987b
Galasko CSB, Courtney P, Jayne M, Coxhead, Rüssel S. Comparison of the efficacy of naproxen sodium and dihydrocodeine tartrate in the treatment of post-operative pain. Current Medical Research and Opinion 10: 656–662, 1988
Gamst ON. Oral naproxen formulations. Scandinavian Journal of Gastroenterology 24 (Suppl. 163): 44–47, 1989
Gamst ON, Vesje AK, Aarbakke J. Bioavailability of naproxen sodium suppositories. International Journal of Clinical Pharmacology, Therapy and Toxicology 22: 99–103, 1984
Garber EK, Guth PH, Silpa ML, Stolz A. A single blind randomized endoscopic study comparing the effects of diflunisal and naproxen in patients with osteoarthritis. Journal of Rheumatology 13: 784–788, 1986
Gasparich JP, Mayo ME. Comparative effects of four prostaglandin synthesis inhibitors on the obstructed kidney in the dog. Journal of Urology 135: 1088–1090, 1986
Geczy M, Peltier L, Wolbach R. Naproxen tolerability in the elderly: a summary report. Journal of Rheumatology 14: 348–354, 1987
Giarelli L, Falconieri G, Delendi M. Fulminant hepatitis following naproxen administration. Human Pathology 17: 1079, 1986
Gil JR, Lavin MM. Estudio de la eficacia y tolerancia de tres fármacos antiinflamatorios no esteroides. Investigatión Médica Internacional 10: 342–349, 1983
Ginsberg F, Famaey JP. A double-blind, parallel trial of oxaprozin versus naproxen in the treatment of osteoarthritis. Current Therapeutic Research and Opinion 8: 689–695, 1984
Goldberg MA. A multicenter study of the safety and efficacy of naproxen: analysis of blood pressure. Seminars in Arthritis and Rheumatism 17 (Suppl. 2): 23–28, 1988
Goldberg MA, Hirose H, McLaughlin GE, Akeson W, Kieffer DA, et al. Naproxen sodium: comparative efficacy and tolerability of two dosages for pain after joint surgery. Orthopedics 11: 575–580, 1988
Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism 29: 1371–1377, 1986
Gonik B, Loo LS, Bigelow R, Kohl S. Influence of naproxen therapy on natural killer cytotoxicity and antibody-dependent cellular cytotoxicity against cells infected with herpes simplex virus. Journal of Reproductive Medicine 29: 722–726, 1984
Gordin A, Sotka S, Nuutila J. Comparison of a slow-release indomethacin tablet and naproxen in osteoarthritis. Current Medical Research and Opinion 9: 500–504, 1985
Gøtzsche PC, Andreasen F, Egsmose C, Lund B. Steady state pharmacokinetics of naproxen in elderly rheumatics compared with young volunteers. Scandinavian Journal of Rheumatology 17: 11–16, 1988
Grace EM, Mewa A, Rooney PJ, Buchanan WW. Clinical therapeutic trial of sodium meclofenamate and naproxen in rheumatoid arthritis, with comments on the use of placebos in clinical trials. Current Medical Research and Opinion 8: 417–424, 1983
Grattan CEH. Generalised eruptive pustular drug rash due to naproxen. Dermatologica 179: 57–58, 1989
Grattan CEH, Kennedy CTC. Naproxen induced erythema nodosum. Abstract. British Medical Journal 288: 114, 1984
Graziani G, Abbiati GA, Dolfini E, Testa R, Velo GP. Pharmacokinetic, pharmacodynamic, and toxicological properties of naproxen gel in laboratory animals. Current Therapeutic Research 42: 480–490, 1987
Greb WH, vonSchrader HW, Cerlek S, Dominis M, Hauptmann E, et al. Endoscopic studies of nabumetone in patients with rheumatoid arthritis. American Journal of Medicine 83 (Suppl. 4B): 19–24, 1987
Grimaldi R, Lecchini S, Crema F, Perucca E. In vivo plasma protein binding interaction between valproic acid and naproxen. European Journal of Drug Metabolism and Pharmacokinetics9: 359–363, 1984
Haataja M, Paul R, Grönroos M, Erkkola R, Punnonen R, et al. Effect of prostaglandin inhibitor and oestrogen on climacteric symptoms and serum free fatty acids. Maturitas 5: 263–269, 1984
Habbema L, Bruynzeel DP. Fixed drug eruption due to naproxen. Dermatologica 174: 184–185, 1987
Hall P, MacLachlan N, Thorn N, Nudd MWE, Taylor CG, et al. Control of menorrhagia by the cyclo-oxygenase inhibitors naproxen sodium and mefenamic acid. British Journal of Obstetrics and Gynaecology 94: 554–558, 1987
Hansten PD, Horn JR. Methotrexate and nonsteroidal anti-inflammatory drugs. Drug Interactions Newsletter 6: 41–44, 1986a
Hansten PD, Horn JR. Nonsteroidal anti-inflammatory drugs: effects on antihypertensive activity of beta-blockers. Drug Interactions Newsletter 6: 1–4, 1986b
Hardy JG, Evans DF, Zaki I, Clark AG, Tönnesen HH, et al. Evaluation of an enteric coated naproxen tablet using gamma scintigraphy and pH monitoring. International Journal of Pharmaceutics 37: 245–250, 1987
Harry DJ, Hicks H. Naproxen reactions in aspirin-hypersensitive patients. Hospital Formulary 18: 648–649, 1983
Hazleman BL, Thomas PP. Single-blind comparative study of nabumetone (Relafer) versus naproxen in the treatment of rheumatoid arthritis. American Journal of Medicine 83 (Suppl. 4B): 60–64, 1987
Hedenbro JL, Wetterberg P, Vallgren S, Bergqvist L. Lack of correlation between fecal blood loss and drug-induced gastric mucosal lesions. Gastrointestinal Endoscopy 34: 247–251, 1988
Heymann WR, Lerman JS, Luftschein S. Naproxen-induced lichen planus. Journal of the American Academy of Dermatology 10: 299–301, 1984
Hodge RH. Double-blind crossover comparison of piroxicam and naproxen in the treatment of active osteoarthritis. Seminars in Arthritis and Rheumatism 3 (Suppl. 1): 3–6, 1985
Howard AM, Dowling J, Varigos G. Pseudoporphyria due to naproxen. Lancet 1: 819–820, 1985
Hunt JN, Smith JL, Jiang CL. Gastric bleeding and gastric secretion with sulindac and naproxen. Digestive Diseases and Sciences 28: 169–173, 1983
Husby G. The Norwegian multicentre study. American Journal of Medicine 81 (Suppl. 5B): 6–10 1986
Husby G, Holme I, Rugstad HE, Herland OB, Giercksky K-E. A double-blind multicentre trial of piroxicam and naproxen in osteoarthritis. Clinical Rheumatology 5: 84–91, 1986
Huskisson EC. Greenwood. Naproxen and piroxicam: a comparative trial in rheumatoid arthritis. European Journal of Rheumatology and Inflammation 6: 242–246, 1983
Ingemanson C-A, Sikström B. Comparison between diclofenac and naproxen in the treatment of primary dysmenorrhea. Current Therapeutic Research 36: 1203–1209, 1984
Jamali F, Stevens DRS. Naproxen excretion in milk and its uptake by the infant. Drug Intelligence and Clinical Pharmacy 17: 910–911, 1983
Janke PG, Diggins JB, Currie WJC, Dasgupta PK, Glick EN, et al. A multi-centre study of sulindac versus naproxen in the treatment of elderly osteoarthritis patients. Pharmacotherapeutica 3: 663–667, 1984
Johnsen V, Bjerkhoel F, Bjørneboe O, Børresen B, Finstad R, et al. Duration of morning stiffness in rheumatic patients after medication with enteric-coated and plain naproxen tablets. Scandinavian Journal of Rheumatology 15: 37–40, 1986
Johnson ES, Ratcliffe DM, Wilkinson M. Naproxen sodium in the treatment of migraine. Cephalalgia 5: 5–10, 1985
Judd LE, Henderson DW, Hill DC. Naproxen-induced pseudoporphyria. Archives of Dermatology 122: 451–454, 1986
Kajanoja P, Kauste K. Diflunisal compared with naproxen in the treatment of dysmenorrhea. Prostaglandins Leukotrienes and Medicine 15: 153–158, 1984
Kajanoya P, Vesanto T. Naproxen and indomethacin in the treatment of primary dysmenorrhea. Acta Obstetrica et Gynecologica Scandinavica 87 (Suppl.): 87–89, 1979
Kamper AL, Strandgaard S, Christensen P, Svendsen UG. Effects of sulindac and naproxen in patients with chronic glomerular disease. Scandinavian Journal of Rheumatology 62 (Suppl.): 26–31, 1986
Kapadia L. A study of naproxen sodium and ibuprofen in primary dysmenorrhoea. Journal of the Society of Occupational Medicine 37: 77–80, 1987
Katona G, Vargas RB. Double-blind crossover study to evaluate the efficacy of a single daily dose of naproxen in rheumatoid arthritis. European Journal of Rheumatology and Inflammation 6: 233–241, 1983
Kauffmann RE, Bolliger RO, Wan SH, Oren J. Pharmacokinetics and metabolism of naproxen in children. Developmental Pharmacology and Therapeutics 5: 143–150, 1982
Kauppila A, Rönnberg L. Naproxen sodium in dysmenorrhea secondary to endometriosis. Obstetrics and Gynecology 65: 379–383, 1985
Kaye RL, Smith RD, Gordon RS, Sack B, Menander-Huber KB. Comparative efficacy and tolerability of naproxen 750mg once daily and naproxen 375mg twice daily in the management of rheumatoid arthritis. Proceedings of the 15th International Congress of Rheumatology (ILAR), pp. 26–27, Jun 21–27, 1981, Paris, 1982
Kelly JG, Kinney CD, Devane JG, Mulligan S, Colgan BV. Pharmacokinetic properties and clinical efficacy of once-daily sustained-release naproxen. European Journal of Clinical Pharmacology 36: 383–388, 1989
Khan FM. A six-month parallel group comparison of fenbüfen and naproxen in the treatment of rheumatoid arthritis. Clinical Therapeutics 5: 483–487, 1983
Kiang C-H, Lee C, Kushusky S. Isolation and identification of 6-desmethylnaproxen sulfate as a new metabolite of naproxen in human plasma. Drug Metabolism and Disposition 17: 43–48, 1989
Koopmans PP, Thien T, Gribnau FWJ. Influence of non-steroidal anti-inflammatory drugs on diuretic treatment of mild to moderate essential hypertension. British Medical Journal 289: 1492–1494, 1984
Kucharz EJ, Hawryiuk D. Effect of acetylsalicylic acid and naproxen on collagen solubility and heterogeneity in the rat liver. Pharmozie 42: 117–118, 1987
Kvarnes L. Naproxen sodium versus pentazocine in treating postoperative pain. Current Therapeutic Research 46: 259–268, 1989
Kvien TK, Høyeraal HM, Sandstad B. Naproxen and acetylsalicylic acid in the treatment of pauciarticular and polyarticular juvenile rheumatoid arthritis. Scandinavian Journal of Rheumatology 13: 342–350, 1984
Lalos O, Nilsson B. Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. International Journal of Gynaecology and Obstetrics 21: 33–37, 1983
Landgren BM, Lundström V, Eneroth P, Johannisson E. The effect of a prostaglandin synthetase inhibitor on the hormonal profile and the endometrium in women. American Journal of Obstetrics and Gynaecology 151: 361–368, 1985
Langrick AF. A study of naproxen sodium and mefenamic acid in primary dysmenorrhoea. British Journal of Clinical Practice 37: 342–347, 1983
Langrick AF, Gunn ADG. A comparison of naproxen sodium and a dextropropoxyphene/paracetamol combination in the treatment of primary dysmenorrhoea in university health centres. British Journal of Clinical Practice 36: 181–184, 1982
Lanza FL, Nelson RS, Rack MF. A controlled endoscopic study comparing the toxic effects of sulindac, naproxen, aspirin, and placebo on the gastric mucosa of healthy volunteers. Journal of Clinical Pharmacology 24: 89–95, 1984
Lanza F, Rack MF, Lynn M, Wolf J, Sanda M. An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa. Journal of Rheumatology 14: 338–341, 1987
Lanza FL, Rack MF, Royer GL, Seckman CE, Gernaat CM, et al. Gastro-intestinal effects of ibuprofen, naproxen and aspirin in normal volunteers. Clinical Trials Journal 23: 168–177, 1986
Laothavorn P, Prichanond S. Effect of naproxen on exercise tolerance test in the chronic stable ischemic heart disease patients. Abstract no. PS 231. Journal of the Medical Association of Thailand 67 (Suppl.): 68, 1985
Lari S, Coli A, Mattioli R, Borghi B, Fabbri G. Acute postsurgical pain in orthopedic surgery: a comparison of sodium naproxen and pentazocine in several analgesic protocols. Current Therapeutic Research 43: 689–697, 1988
Larsen A. Piroxicam versus naproxen in rheumatoid arthritis: a double-blind,cross-over study. International Journal of Clinical Pharmacology Research 5: 17–23, 1985
Laxer RM, Silverman ED, Balfe JW, Poucell S, Baumal R. Naproxen-associated renal failure in a child with arthritis and inflammatory bowel disease. Pediatrics 80: 904–908, 1987
Leak AM, Richter MR, St Cyr C, Ansell BM. Flurbiprofen is as effective as naproxen in juvenile spondylitis. Journal of Rheumatology 13: 664–665, 1986
Leatham PA, Bird HA, Wright V, Seymour D, Gordon A. A double blind study of antrafenine, naproxen and placebo in osteoarthrosis. European Journal of Rheumatology and Inflammation 6: 209–211, 1983
Lee DKH. Effect of etodolac on the prostaglandin concentrations in the kidney of the normal rat. Drug Development Research 9: 305–311, 1986
Lereim P, Gabor I. Piroxicam and naproxen in acute soft tissue injuries. European Journal of Rheumatology and Inflammation 8: 109–111, 1985
Lewis RV. Severe asthma after naproxen. Lancet 1: 1270, 1987
Lindegaard KF, Øvrelid L, Sjaastaad O. Naproxen in the prevention of migraine attacks. A double-blind placebo-controlled cross-over study. Headache 20: 96–98, 1980
Lindsley CB, Warady BA. Nonsteroidal antiinflammatory drugs: renal toxicity. Clinical Pediatrics 29: 10–13, 1990
Ling TL, Yee JP, Cohen A, Hsiao C, Gonzalez MA, et al. A multiple-dose pharmacokinetic comparison of naproxen as a once-daily controlled-release tablet and a twice-daily conventional tablet. Journal of Clinical Pharmacology 27: 325–329, 1987
Lizarazo PH, Cortés MP. Single-blind parallel study comparing naproxen with sulindac and with diclofenac in rheumatoid arthritis. Current Therapeutic Research 34: 701–707, 1983
Lo TCN, Martin MA. Autoimmune haemolytic anaemia associated with naproxen suppositories. British Medical Journal 292: 1430, 1986
Londino AV, Wolf GL, Calabro JJ, Perrone SJ. Naproxen and pneumonitis. Journal of the American Medical Association 252: 1853, 1984
López Sánchez J, Yañez Marchena G. Meclofenamate sodium, phenylbutazone and naproxen in the treatment of degenerative joint disease. Arzneimittel-Forschung 33: 653–656, 1983
Luggen ME, Gartside PS, Hess EV. Nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Duration of use as a measure of relative value. Journal of Rheumatology 16: 1565–1569, 1989
Lundström V, Landgren BM, Eneroth P, Johannesson E. The effect of a prostaglandin synthetase inhibitor on the hormonal profile and the endometrium in women. Acta Obstetrica et Gynecologica Scandinavica 113 (Suppl.): 77–80, 1983
Lussier A, Arsenault A, Varady J, de Médicis R, Lussier Y, et al. The use of a 51 Cr technique to detect gastrointestinal microbleeding associated with nonsteroidal antiinflammatory drugs. Seminars in Arthritis and Rheumatism 17 (Suppl. 2): 40–45, 1988
Mactier RA, Khanna R. Hyperkalemia induced by indomethacin and naproxen and reversed by fludrocortisone. Southern Medical Journal 81: 799–801, 1988
Manchester General Practitioner Group. A study of naproxen and ibuprofen in patients with osteoarthritis seen in general practice. Current Medical Research and Opinion 9: 41–46, 1984
Mann PG. A comparison between furoprofen calcium and naproxen sodium in the treatment of soft tissue sports injuries. Pharmatherapeutica 3: 499–504, 1983
Marchini M, Fedele L, Garagiola V, Maresca V. Pirprofen, naproxen and placebo in the treatment of primary dysmenorrhoea. Drugs Under Experimental and Clinical Research 13: 699–705, 1987
Marsala F, Cavrini P, Bufalino L, Cardini F. Treatment of acute pain of ureteral and biliary colic with naproxen sodium administered by the parenteral route. International Clinical and Pharmacological Research 6: 495–500, 1986
Martel RR, Klicius J, Metcalf G. Effect of etodolac on articular and bone pathology associated with adjuvant arthritis in rats: a comparison with aspirin and naproxen. Agents and Actions 14: 257–264, 1984a
Martel RR, Klicius J, Metcalf G, Rona GA. Comparative effects of long term treatment with etodolac, naproxen and ibuprofen on articular and bone changes associated with adjuvant arthritis in rats. Agents and Action 15: 403–412, 1984b
Martin PJ, Higginbotham HL. Naproxen simulating 5-hydroxyindoles. Abstract. British Medical Journal 288: 1346, 1984
Martinez R, Smith DW, Frankel LR. Severe metabolic acidosis after acute naproxen sodium ingestion. Annals of Emergency Medicine 18: 1102–1104, 1989
Mathew NT. Amelioration of ergotamine withdrawal symptoms with naproxen. Headache 27: 130–133, 1987
Mayon S, Black MM. Pseudoporphyria due to naproxen. British Journal of Dermatology 114: 519–520, 1986
Mbuyi-Muamba JM, Dequeker J. Piroxicam versus naproxen in rheumatoid arthritis. Current Medical Research and Opinion 8: 612–617, 1983
McCulloch PG, Holden P, Robson DJ, Rowley DI, Norris SH. The value of mobilisation and non-steroidal anti-inflammatory analgesia in the management of inversion injuries of the ankle. British Journal of Clinical Practice 39: 69–72, 1985
Mcllwain HH, Platt RD. Piroxicam versus naproxen in the treatment of acute musculoskeletal disorders in athletes. American Journal of Medicine 84 (Suppl. 5A): 56–60, 1988
McLaughlin G. Choline magnesium trisalicylate vs. naproxen in rheumatoid arthritis. Current Therapeutic Research 32: 579–585, 1982
McNeil P, MacKenzie I, Manoharan A. Naproxen-associated aplastic anaemia. Medical Journal of Australia 145: 53–54, 1986
McVerry RM, Lethbridge J, Martin N, Mukerjee SK, Littler T, et al. Pharmacokinetics of naproxen in elderly patients. British Journal of Clinical Pharmacology 21: 606P–607P, 1986a
McVerry RM, Lethbridge J, Martin N, Mukerjee SK, Littler T, et al. Pharmacokinetics of naproxen in elderly patients. European Journal of Clinical Pharmacology 31: 463–468, 1986b
Miller DS, Talbot CA, Simpson W, Korey A. A comparison of naproxen sodium, acetaminophen and placebo in the treatment of muscle contraction headache. Headache 27: 392–396, 1987
Milsom I, Andersch B. Effect of ibuprofen, naproxen sodium and paracetamol on intrauterine pressure and menstrual pain in dysmenorrhoea. British Journal of Obstetrics and Gynaecology 91: 1129–1135, 1984
Milsom I, Andersch B. Ibuprofen and naproxen-sodium in the treatment of primary dysmenorrhea: a double-blind cross-over study. International Journal of Gynaecology and Obstetrics 23: 305–310, 1985
Milsom I, Andersch B, Sundeil G. The effect of flurbiprofen and naproxen sodium on intra-uterine pressure and menstrual pain in patients with primary dysmenorrhea. Acta Obstetrica et Gynecologica Scandinavica 67: 711–716, 1988
Mitchell RA, Woolf D, Murray-Leslie C, Huskisson EC, Wojtu-lewski J, et al. Problems in assessing the possible disease-modifying effect of naproxen. British Journal of Clinical Practice 41: 560–565, 1987
Mordes JP. Possible naproxen-associated vasculitis. Archives of Internal Medicine 140: 985, 1980
Mowat AM, Mowat AG, Jones CW, Engler C. A comparison of once and twice daily naproxen in rheumatoid arthritis. British Journal of Clinical Practice 38: 95–98, 1984
Moyer S. Pharmacokinetics of naproxen sodium. Cephalalgia 6 (Suppl. 4): 77–80, 1986
Mroszczak E, Runkel R, Roe R, Ortega E, Segre E. Naproxen pharmacokinetics and metabolism in renal failure. Abstract no. 0544. Presented at the World Conference in Clinical Pharmacology and Therapeutics, London, Aug 3–9, 1988a
Mroszczak E, Yee JP, Bynum L. Absorption of naproxen-controlled release tablets in fasting and postprandial volunteers. Journal of Clinical Pharmacology 28: 1128–1131, 1988b
Mugnier A, Schneck G, Champion P, Mignon H. Douleurs postopératoires: étude comparative de l’action antalgique du naproxène sodique et du paracétamol. Presse Médicale 13: 429–431, 1984
Mungavin JM, Clarke TK. A multi-centre study of tiaprofenic acid (’surgam’) and five comparative drugs in rheumatoid arthritis and osteoarthritis in general practice. Current Medical Research and Opinion 8: 461–471, 1983
Nader DA, Schillaci RF. Pulmonary infiltrates with eosinophilia due to naproxen. Chest 83: 280–284, 1983
Nestvold K. Naproxen and naproxen sodium in acute migraine attacks. Cephalalgia 6 (Suppl. 4): 81–84, 1986
Nestvold K, Kloster R, Partinen H, Sulkava R. Treatment of acute migraine attack: naproxen and placebo compared. Cephalalgia 5: 115–119, 1985
Ng HWK, MacFarlane AW, Graham RM, Verbov JL. Near fatal drug interactions with methotrexate given for psoriasis. British Medical Journal 295: 752–753, 1987
Nielsen CB. Prostaglandin inhibition and central corneal thickness after cataract extraction. Acta Ophthalmologica 60: 252–258, 1982
Nielsen CB. The effect of the prostaglandin-inhibitor naproxen on the endothelial cell-loss after cataract extraction. Acta Ophthalmologica 61: 102–107, 1983
Nørrelykke Nissen J, Ehlers N. No additive effect of tranexamic acid and naproxen on corneal deswelling. Acta Ophthalmo-Iogica 64: 291–294, 1986
Nygard N, Starkebaum G. Naproxen and agranulocytosis. Journal of the American Medical Association 257: 1732, 1987
Nygren KG, Rybo G. Prostaglandins and menorrhagia. Acta Obstetrica et Gynecologica Scandinavica 113 (Suppl.): 101–103, 1983
Oddsson E, Gudjónsson H, Thjodleifsson B. Endoscopic findings in the stomach and duodenum after treatment with enteric coated and plain naproxen tablets in healthy subjects. Scandinavian Journal of Gastroenterology 24 (Suppl. 159): 60, 1989
Osborn TG, Parks RL, Moore TL, Grisanti MW, Nesher G, et al. Diflunisal versus naproxen in the management of rheumatoid arthritis. Clinical Therapeutics 11: 736–743, 1989
Ouellette RD, Feinberg A, Laraja R, Rothenberg RE, Welch GW. Naproxen sodium vs acetaminophen plus codeine in post-surgical pain. Current Therapeutic Research 39: 839–845, 1986
Owen PR. Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhea. American Journal of Obstetrics and Gynecology 148: 96–103, 1984
Page SR, Grattan CEH. Pustular reaction to naproxen with cholestatic jaundice. Abstract. British Medical Journal 293: 510, 1986
Pagliara L, Baldelli A, Sanguineti F, Siri R. Proxen in the treatment of gonarthrosis. A controlled clinical double-blind study. Drugs under Experimental and Clinical Research 12: 929–932, 1986
Pedrón N, Aznar R. Effect of naproxen on IUD-induced hypermenorrhea. Contraceptive Delivery Systems 4: 39–42, 1983
Pérez-Baspino J, Vaca-Vaca JM, Corbaláan AJ, Brugger AJ. Quantitative study of the uterus-inhibiting activity of sodium naproxen in rat isolated uterus. Methods and Findings in Experimental and Clinical Pharmacology 5: 625–629, 1983
Petri M, Dobrow R, Neiman R, Whiting-O’Keefe Q, Seaman WE. Randomized, double-blind, placebo-controlled study of the treatment of the painful shoulder. Arthritis and Rheumatism 30: 1040–1045, 1987
Physicians Desk Reference. Naprosyn®. 43 Edition, pp. 2140–2142, Medical Economics Company Inc., New Jersey, 1989
Pisko EJ, Bockow BI, Box P, Brodsky AL, Burch FX, et al. Six-month multi-center study comparing nabumetone with naproxen in the treatment of osteoarthritis. American Journal of Medicine 83 (Suppl. 4B): 86–91, 1987
Plantema F. Worldwide studies comparing piroxicam with naproxen. Acta Obstetrica et Gynecologica 138: 15–17, 1986
Poiley JE. Nabumetone versus naproxen in the treatment of osteoarthritis. American Journal of Medicine 83 (Suppl. 4B): 82–85, 1987
Pradalier A, Rancivel G, Dordain G, Verdive L, Rascol A, et al. Acute migraine attack therapy: comparison of naproxen sodium and an ergotamine tartrate compound. Cephalalgia 5: 107–113, 1985
Pritchett PM, Jay WM, Aziz MZ, Green K. The effect of naproxen on the ocular inflammatory response following extracapsular lens extraction in rabbits. Acta Ophthalmologica 63: 519–524, 1985
Ragheb M, Powell AL. Lithium interaction with sulindac and naproxen. Journal of Clinical Psychopharmacplogy 6: 150–154, 1986
Rameis H, Hitzenberger G, Liem KS, Hulkenberg-Tromp D. Comparison of gastrointestinal blood loss induced by cloximate in two formulations and by naproxen. International Journal of Clinical Pharmacology, Therapy and Toxicology 22: 96–98, 1984
Ravi S, Keat AC, Keat ECB. Colitis caused by non-steroidal antiinflammatory drugs. Postgraduate Medical Journal 62: 773–776, 1986
Ray PE, Rigolizzo D, Wara DR, Piel CF. Naproxen nephrotoxicity in a 2-year-old child. American Journal of Diseases in Children 142: 524–525, 1988
Reeve PA, Moshiri M, Bell GD. Pulmonary oedema, jaundice and renal impairment with naproxen. British Journal of Rheumatology 26: 70–71, 1987
Richards AM, Burry HC, Treadwell DU, Tweed JM, Mowles E. Nabumetone, a new non-steroidal anti-inflammatory drug: a comparison with naproxen. New Zealand Medical Journal 96: 1015–1016, 1983
Roth SH. Endoscopy-controlled study of the safety of nabumetone compared with naproxen in arthritis therapy. American Journal of Medicine 83 (Suppl. 4B): 25–30, 1987
Roth SH. Naproxen: antirheumatic efficacy and safety in patients with pre-existing gastrointestinal disease. Seminars in Arthritis and Rheumatism 17 (Suppl. 2): 36–39, 1988a
Roth SH. Nonsteroidal anti-inflammatory drugs: gastropathy, deaths, and medical practice. Annals of Internal Medicine 109: 353–354, 1988b
Roth SH. Pharmacologic approaches to musculoskeletal disorders. Clinics in Geriatric Medicine 4: 441–461, 1988c
Rothenberg RJ, Sufit RL. Drug-induced peripheral neuropathy in a patient with psoriatic arthritis. Arthritis and Rheumatism 30: 221–224, 1987
Rugstad HE. The Norway study: plasma concentrations, efficacy, and adverse events. American Journal of Medicine 81 (Suppl. 5B): 11–14, 1986
Rugstad HE, Hundal Ø, Holme I, Herland DB, Huby G, et al. Piroxicam and naproxen plasma concentrations in patients with osteoarthritis: relation to age, sex, efficacy and adverse events. Clinical Rheumatology 5: 389–398, 1986
Ryan JR, Chremos AN, Vargas R, Johnson CL, McMahon FG. The influence of non steroidal anti-inflammatory drugs (NSAID), [sulindac (S) and naproxen (N)] on natriuretic, diuretic and renin (PRA) response to furosemide (F). Abstract no. C33. Clinical Pharmacology and Therapeutics 35: 271, 1984
Ryan J, McMahan F, Vargas R, Gotzkowsky S, McNamara D, et al. Effects of salsalate, aspirin and naproxen on plasma renin activity (PRA).and platelet thromboxane (T2 B2 ) synthesis. Abstract no. E66. Arthritis and Rheumatology 29 (Suppl.): S103, 1986
Rybo G, Nilsson S, Sikström B, Nygren KG. Naproxen in menorrhagia. Lancet 1: 608–609, 1981
Ryley NJ, Lingam G. A pharmacokinetic comparison of controlled-release and standard naproxen tablets. Current Medical Research and Opinion 11: 10–27, 1988
Salom IL, Jacob G, Jallad N, Perdomo CA, Mullane JF, et al. Gastrointestinal microbleeding associated with the use of etodolac, ibuprofen, indomethacin, and naproxen in normal males. Journal of Clinical Pharmacology 24: 240–246, 1984
Sargent JD, Baumel B, Peters K, Diamond S, Saper JR, et al. Aborting a migraine attack: naproxen sodium v. ergotamine plus caffeine. Headache 28: 263–266, 1988a
Sargent JD, Peters K, Goldstein J, Madison DS, Solbach P. Naproxen sodium for muscle contraction headache treatment. Headache 28: 180–182, 1988b
Sargent J, Solbach P, Alger J, Damasio H, Baumel B, et al. A comparison of naproxen sodium to propranolol hydrochloride or a placebo control for the prophylaxis of migraine headache. Abstract no. 11. Headache 24: 164, 1984
Scarpa R, Pucino A, Riccio A, Farinaro C, Oriente P. Clinical evaluation of analgesic effect of parenterally administered sodium naproxen (Axer Alfa) in osteoarthritis. Clinical Trials Journal 23: 77–80, 1986
Scharf Y, Nahir M, Schapira D, Lorber M. A comparative study of naproxen with diclofenac sodium in osteoarthrosis of the knees. Rheumatology and Rehabilitation 21: 167–170, 1982
Schorn D. A comparative study of isoxicam and naproxen in rheumatoid arthritis. South African Medical Journal 67: 452–454, 1985
Schuna AA, Vejraska BD, Hiatt JG, Kochar M, Day R, et al. Lack of interaction between sulindac or naproxen and propranolol in hypertensive patients. Journal of Clinical Pharmacology 29: 524–528, 1989
Schwartzman M, D’Agati V. Spontaneous relapse of naproxen-related nephrotic syndrome. American Journal of Medicine 82: 329–332, 1987
Scoren RD, Corn H, Rhodes P, Schwarz M, Segal PL, et al. Pain following peridontal surgery: treatment with a nonnarcotic analgesic compared with two iodine combinations. Current Therapeutic Research 42: 463–471, 1987
Sekker W, Schönmehl W, Rohde HJ, Brackertz D. Klinische Prüfung von Purprofen und Naproxen bei Patienter mit Gon- und Coxarthrosen. Fortschritte der Medizin 103: 182–184, 1985
Seppälä E, Nissilä M, Isomäki H, Nuotio P, Nykänen E, et al. Comparison of the effects of different anti-inflammatory drugs on synovial fluid prostanoid concentrations in patients with rheumatoid arthritis. Clinical Rheumatology 4: 315–320, 1985
Sevelius H, Runkel R, Segre E, Bloomfield SS Bioavailability of naproxen sodium and its relationship to clinical analgesic effects. British Journal of Clinical Pharmacology 10: 259–263, 1980
Shah J, Mroszczak E, Bynum L, Fratis A, Kiang C. Bioequivalence comparison of enteric-coated (EC) naproxen versus standard naproxen tablets. Abstract 1613. Pharmaceutical Research 6 (Suppl): S232, 1989
Sheehan NJ. Pulmonary infiltrates and eosinophilia associated with naproxen. British Journal of Rheumatology 24: 302–305, 1985
Shelley ED, Shelley WB, Burmeister V. Naproxen-induced pseudoporphyria presenting a diagnostic dilemma. Cutis 40: 314–316, 1987
Shelley WB, Elpern DJ, Shelley ED. Naproxen-photosensitization demonstrated by challenge. Cutis 38: 169–170, 1986
Shupp DL, Schroeter AL. An unusual case of salicylate toxicity. Journal of the American Academy of Dermatology 15: 300–301, 1986
Siddle NC, Young O, Sledmere CM, Reading AE, Whitehead. A controlled trial of naproxen sodium for relief of pain associated with Vabra suction curettage. British Journal of Obstetrics and Gynaecology 90: 864–869, 1983
Simmons RLL, Owen S, Abbott CJA, Bouchier-Hayes TAI, Hunt HA. Naproxen sodium and paracetamol/dextropropoxyphene in sports injuries — a multicentre comparative study. British Journal of Sports Medicine 16: 91–95, 1982
Sindet-Pedersen S, Petersen JK, Gøtzsche PC, Christensen H. A double-blind randomised study of naproxen and acetylsalicylic acid after surgical removal of impacted lower third molars. International Journal of Oral and Maxillofacial Surgery 15: 389–394, 1986
Singh RR, Malavuja AN, Pardey JN, Guleria JS. Fatal interaction between methotrexate and naproxen. Lancet1: 1390, 1986
Singhal PC, Faulkner M, Venkatesan J, Molho L. Hypersensitivity angiitis associated with naproxen. Annals of Allergy 63: 107–109, 1989
Smith DL, McAsee JH, Lucas LM, Kumar KL, Romney DM. Treatment of nonseptic olecranon bursitis. Archives of Internal Medicine 149: 2527–2530, 1989
Smith MD, Thomas D, McCredie M, Brooks PM. Piroxicam versus naproxen in the treatment of painful shoulder. Pharmatherapeutica 4: 585–589, 1986
Solheim LF, Rönningen H, Barth E, Langeland N. Effects of acetylsalicylic acid and naproxen on the mechanical and biochemical properties of intact skin in rats. Scandinavian Journal of Plastic and Reconstructive Surgery 20: 161–163, 1986a
Solheim LF, Rönningen H, Langeland N. Effects of acetylsalicylic acid and naproxen on the synthesis and mineralization of collagen in the rat femur. Archives of Orthopaedic and Traumatic Surgery 105: 1–4, 1986b
Solheim LF, Rönningen H, Langeland N. Effects of acetylsalicylic acid and naproxen on the mechanical properties of intact femora in rats. Archives of Orthopaedic and Traumatic Surgery 105: 5–10, 1986c
Solheim LF, Rönningen H, Langeland N. Effects of acetylsalicylic acid and naproxen on bone resorption and formation in rats. Archives of Orthopaedic and Traumatic Surgery 105: 137–141, 1986d
Stacher G, Bauer P, Schneider C, Winklehner S, Schmierer G. Effects of a combination of oral naproxen sodium and codeine on experimentally induced pain. European Journal of Clinical Pharmacology 21: 485–490, 1982
Stull PA, Jobl P. Comparison of diflunisal and naproxen in the treatment of tennis elbow. Clinical Therapeutics 9 (Suppl. C): 62–66, 1986
Sterling JC, Pye RJ. Naproxen-induced pseudoporphyria. British Journal of Rheumatology 26: 210–211, 1987
Suprapto K, Reed S. Naproxen sodium for pain relief in first-trimester abortion. American Journal of Obstetrics and Gynecology 150: 1000–1001, 1984
Svendsen VG. Effects of sulindac and naproxen on patients with glomerulonephritis and moderately impaired renal function. Abstract. Scandinavian Journal of Rheumatology 59 (Suppl.): 94, 1986
Svendsen VG, Gerstoft J, Hansen TM, Christensen P, Lorenzen I. The renal excretion of prostaglandins and changes in plasma renin during treatment with either sulindac or naproxen in patients with rheumatoid arthritis and thiazide treated heart failure. Journal of Rheumatology 11: 779–782, 1984
Sylvia LM, Forlenza SW. Brocavich JM. Aseptic meningitis associated with naproxen. Drug Intelligence and Clinical Pharmacy 22: 399–401, 1988
Szmyd L, Perry HD. Keratopathy associated with the use of naproxen. American Journal of Ophthalmology 99: 598, 1985
Szórády I, Martonyi E, Santa A. Antipyretic effect of naproxen in children. Therapie 43: 155, 1988
Taborn J, Anderson S, Goldberg M, Kantrowitz F, Menander-Huber K, et al. Relief of morning stiffness: a comparative study of naproxen and ibuprofen. Current Medical Research and Opinion 9: 359–365, 1985
Taborn JD, Burch FX, Caldwell JR, Kantrowitz FG, Louie JS, et al. Comparative study of once a day dosing with naproxen versus twice a day dosing of sulindac in patients with rheumatoid arthritis. Proceedings of the 15th International Congress of Rheumatology (ILAR), Jun 21–27, 1981, Paris, pp. 23–25, 1982
Tannenbaum H, Esdaile J, Topp JR, Prat A, Rostogi RB, et al. A double-blind, multicenter, controlled study on diclofenac (Voltaren®) and naproxen in patients with rheumatoid arthritis. Current Therapeutic Research 35: 357–362, 1984
Tütinen S, Nissilä M, Ruutsalo HM, Isomäki H. Effect of non-steroidal anti-inflammatory drugs on the renal excretion of uric acid. Clinical Rheumatology 2: 233–236, 1983
Treves TA, Korizyn AD, Streifler M. Naproxen in the treatment of acute migraine attacks. Abstract. Neurology 36 (Suppl. 1): 101, 1986
Trondstad RI, Aadland E, Holler T, Olaussen B. Gastroscopic findings after treatment with enteric-coated and plain naproxen tablets in healthy subjects. Scandinavian Journal of Gastroenterology 20: 239–242, 1985
Trondstad R, Bell H, Holler T. Endoscopic evaluation of the effect of naproxen tablets and suppositories on the gastric mucosa in healthy volunteers. Scandinavian Journal of Gastroenterology 23 (Suppl. 145): 70, 1988
Turi G, Boscaro C, De Bastiani G. Double-blind comparative study of isoxicam and naproxen in the treatment of patients with osteoarthritis. Current Therapeutic Research 33: 83–88, 1983
Turner R. Hepatic and renal tolerability of long-term naproxen treatment in patients with rheumatoid arthritis. Seminars in Arthritis and Rheumatism 17 (Suppl. 2): 29–35, 1988
Upton RA, Williams RL, Kelly J, Jones RM. Naproxen pharmacokinetics in the elderly. British Journal of Clinical Pharmacology 18: 207–214, 1984
Uribe A, Johannson C, Slezak P, Rubio C. Ulcérations of the colon associated with naproxen and acetylsalicylic acid treatment. Gastrointestinal Endoscopy 32: 242–243, 1986
van den Ouweland FA, Corstens FHM, van de Putte LBA, Gribnau FWJ. Gastrointestinal blood loss during treatment with naproxen for rheumatoid arthritis. Scandinavian Journal of Rheumatology 16: 365–370, 1987a
van den Ouweland FA, Franssen MJAM, van de Putte LBA, Tan Y, van Ginneken CAM, et al. Naproxen pharmacokinetics in patients with rheumatoid arthritis during active polyarticular inflammation. British Journal of Clinical Pharmacology 23: 189–193, 1987b
van den Ouweland FA, Gribnau FWJ, van Ginneken CAM, Tan Y, van de Putte LBA. Naproxen kinetics and disease activity in rheumatoid arthritis: a within-patient study. Clinical Pharmacology and Therapeutics 43: 79–85, 1988a
van den Ouweland FA, Gribnau FWJ, Tai Y, van Ginneken CAM, van de Putte. Hypoalbuminaemia and naproxen pharmacokinetics in a patient with rheumatoid arthritis. Clinical Pharmacokinetics 11: 511–515, 1986
van den Ouweland FA, Jansen PAF, Tan Y, van de Putte LBA, van Ginneken CAM, Gribnau FWJ. Pharmacokinetics of high-dosage naproxen in elderly patients. International Journal of Clinical Pharmacology, Therapy and Toxicology 26: 143–147, 1988b
van der Spek P, Warson F, van Overberg L, Peters O. Postoperative jaundice associated with naproxen. Abstract no. 84. Naunyn-Schmiedeberg’s Archives of Pharmacology 330 (Suppl.): R20, 1985
Vasey FB, Germain BF, Espuoza LR, Box P, Bockow BI, et al. Controlled evaluation of nabumetone in the treatment of active adult rheumatoid arthritis. American Journal of Medicine 83 (Suppl. 4B): 55–59, 1987
Vesterqvist O, Green K. Effects of naproxen on the in vivo synthesis of thromboxane and prostacyclin in man. European Journal of Clinical Pharmacology 37: 563–565, 1989
Vetter G. A comparison of naproxen and diclofenac sodium in the treatment of osteoarthritis in elderly patients. British Journal of Clinical Practice 39: 276–281, 1985
Victorino RM, Baptista A, Silveira JC, De Moura MC. Jaundice associated with naproxen. Postgraduate Medical Journal 56: 368–370, 1980
Vitting KE, Nichols NJ, Seligson GR. Naproxen and acute renal failure in a runner. Annals of Internal Medicine 105: 144, 1986
Vriesendorp R, Donker AJM, de Zeeuw D, de Jong PE, van der Hem GK. Antiproteinuric effect of naproxen and indomethacin. American Journal of Nephrology 5: 236–242, 1985
Wallis PJW, Lodwick R, Sirha SK, Constable TJ. Effect of naproxen on renal haemodynamics in elderly patients. Abstract no. 15. British Journal of Rheumatology 26 (Suppl.): 9, 1987
Waltham-Weeks CD. Etodolac versus naproxen in rheumatoid arthritis: a double-blind crossover study. Current Medical Research and Opinion 10: 540–547, 1987
Warrington SJ, Horton M, Davies IB. High dose tiaprofenic acid, naproxen and aspirin: comparison of effects on gastrointestinal blood loss. British Journal of Clinical Pharmacology 18: 301P–302P, 1984
Wasser WG, Goldstern MH, Barba F, et al. Persistent renal failure following administration of naproxen. Mount Sinai Journal of Medicine 49: 127–129, 1982
Watson WA, Freer JP. Effects of naproxen and sulindac in arthritic patients with renal impairment Abstract 26E. Pharmacotherapy 9: 177, 1989
Watson WA, Freer JP, Katz RS, Basch C. Kidney function during naproxen therapy in patients at risk for renal insufficiency. Seminars in Arthritis and Rheumatism 17 (Suppl. 2): 12–16, 1988
Waugh PK, Keatinge DW. Hypoprothrombinemia in naprdxen overdose. Drug Intelligence and Clinical Pharmacy 17: 549–550, 1983
Weber SS, Bankhurst AD, Mroszczak E, Ding TL. Effect of Mylanta® on naproxen bioavailability. Therapeutic Drug Monitoring 3: 75–83, 1981
Webster J. Interactions of NSAIDs with diuretics and β-blockers: mechanisms and clinical implications. Drugs 30: 32–41, 1985
Welch KMA. Naproxen sodium in the treatment of migraine. Cephalalgia 6 (Suppl. 4): 85–92, 1986
White R, De Jager JP, Fleming A. A double-blind crossover trial of diflunisal and naproxen in osteoarthritis. Current Medical Research and Opinion 10: 436–440, 1987
Wilhelmson L, Jaderling J. A double-blind crossover study of piroxicam and naproxen sodium in the treatment of primary dysmenorrhea. Abstract. European Journal of Rheumatology and Inflammation 8: 121–122, 1985
Williams AA, Backhouse CI. A general practice study of naproxen sodium and a dextropropoxyphene-paracetamol combination in primary dysmenorrhoea. British Journal of Clinical Practice 36: 383–385, 1982
Williams PL, Ansell BM, Bell A, Cain ARR, Chamberlain A, et al. Multicentre study of piroxicam versus naproxen in juvenile chronic arthritis, with special reference to problem areas in clinical trials of nonsteroidal anti-inflammatory drugs in childhood. British Journal of Rheumatology 25: 67–71, 1986
Williams RL, Upton RA, Cello JP, Jones RM, Blitstein M, et al. Naproxen disposition in patients with alcoholic cirrhosis. European Journal of Clinical Pharmacology 27: 291–296, 1984
Willkens R, Crain D, Nussdorf RT, Partridge R, Sokoloff M, et al. Naproxen and sulindac in the treatment of osteoarthritis -a crossover comparison. Current Therapeutic Research 34: 45–58, 1983
Wilson Downie W. Comparative studies of isoxicam in rheumatoid arthritis. Seminars in Arthritis and Rheumatism 12 (Suppl. 2): 170–174, 1982
Wiseman RL, Sodergren J, Guttadauria M, Ryan AJ. Treatment of acute musculoskeletal disorders with piroxicam: results of a double-blind multicenter comparison with naproxen. Current Therapeutic Research 42: 974–987, 1987
Wojtecka-Lukasik E, Maslinski S. Polymorphonuclear leukocyte collagenase in carrageenin-induced inflammation: effect of nonsteroidal antiinflammatory drugs. International Journal of Tissue Reactions 8: 321–325, 1986
Wong DG, Spense JD, Lamki L, Freeman D, McDonald JWD. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet 1: 997–1001, 1986
Wu MJ, Kumar KS, Kulkarni G, Kaiser H. Multiple myeloma in naproxen-induced acute renal failure. New England Journal of Medicine 317: 170–171, 1987
Ylikorkala O, Pekonen F. Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia. Obstetrics and Gynecology 68: 10–12, 1986
Zecchi V, Rodriguez L, Tartarini A, Chiarini A, Valenti P. In vitro studies of naproxen and its sodium and piperazine salts. Pharmaceutica Acta Helvetiae 59: 91–94, 1984
Ziegler DK, Ellis DJ. Naproxen in prophylaxis of migraine. Archives of Neurology 42: 582–584, 1985
Author information
Authors and Affiliations
Additional information
Various sections of the manuscript reviewed by: P.M. Brooks, Department of Rheumatology, Royal North Shore Hospital, St Leonards, New South Wales, Australia; J.C. Chang, Department of Medicine, Wright State University School of Medicine, Dayton, Ohio, USA; P. Davis, Department of Rheumatology/Clinical Immunology, University of Alberta, Edmonton, Alberta, Canada; M.A. Goldberg, Passaic Internal Medicine Group, Passaic, New Jersey, USA; F.D. Hart, Harley Street, London, England; G. Husby, Department of Rheumatology, University of Tromsö Institute of Clinical Medicine, Tromsö, Norway; T. Ishizaki, Clinical Research Institute, National Medical Center, Tokyo, Japan; I. Milsom, Department of Obstetrics & Gynaecology, East Hospital, Göteborg, Sweden; M. Orme, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, England; S.H. Roth, Arthritis Center Ltd, Phoenix, Arizona, USA; J.D. Sargent, Headache and Internal Medicine Research Center, The Menninger Clinic, Topeka, Kansas, USA; K. Tsurumi, Department of Pharmacology, Gifu University School of Medicine, Gifu, Japan; J.A. Vale, West Midlands Poisons Unit, Dudley Road Hospital, Birmingham, England; F.A. van den Ouweland, Department of Epidemiology, Erasmus University Rotterdam, Rotterdam, The Netherlands; G. Vetter, Klinik Auerbach, Auerbach, West Germany.
Rights and permissions
About this article
Cite this article
Todd, P.A., Clissold, S.P. Naproxen. Drugs 40, 91–137 (1990). https://doi.org/10.2165/00003495-199040010-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199040010-00006